Dublin, May 13, 2025 (GLOBE NEWSWIRE) -- The "Leqembi Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering.
The Leqembi market report provides an extensive analysis of key market characteristics, including size, growth potential, and segmentation. Offering a detailed regional and national breakdown, the report highlights historical data and growth projections. It also explores the competitive landscape, market share insights, emerging trends, and strategic developments influencing the market.
The historic period witnessed growth due to an increasing elderly population, enhanced funding for neurodegenerative research, improved reimbursement, ongoing clinical trials, and rising healthcare expenditure. The forecast period anticipates growth from greater R&D investments, increased awareness of early Alzheimer's diagnosis, and a heightened demand for treatments. There is also a stronger focus on addressing amyloid plaques, advancements in neuroscience, digital health technologies rise, improvement in Alzheimer's treatments, personalized medicine shift, and disease-modifying therapies development.
Alzheimer's disease prevalence is a primary driver of the Leqembi market. This degenerative brain disorder gradually impacts memory and cognition, influenced by genetic, lifestyle, and environmental factors. Leqembi reduces beta-amyloid plaques, slowing cognitive decline in early Alzheimer's stages by preserving memory and cognitive functions.
For instance, in 2024, the European Brain Council reported approximately 7 million people in Europe live with Alzheimer's, projecting an increase to 14 million by 2030 due to the aging population, illustrating its global public health impact. Innovation in IV maintenance dosing formulations for Alzheimer's therapy fuels the Leqembi market. This method ensures sustained therapeutic levels via direct bloodstream medication delivery. In June 2024, Eisai Co., Ltd., and Biogen Inc. announced FDA acceptance of a supplemental biologics license application for LEQEMBI's monthly IV maintenance regimen.
LEQEMBI targets toxic amyloid proteins, offering potential treatment efficacy extension, reduced neuronal damage, and improved long-term patient outcomes. In November 2024, Biogen Inc. and Eisai Co., Ltd. collaborated to develop Alzheimer's treatments, focusing on Leqembi for early-stage patients. Eisai Co. Ltd. manufactures Leqembi, a key market player.
Regionally, North America was the largest in the Leqembi market for 2024, while Asia-Pacific is projected as the fastest-growing region. The report covers regions including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa, and countries such as the USA, Canada, UK, France, Germany, China, Japan, and others.
Leqembi, a prescription medication for Alzheimer's, targets the neurodegenerative disorder by reducing amyloid-beta plaques. Its formulations include injectable forms such as IV injections for rapid absorption and dosing accuracy. Suitable for adult, geriatric, and early-stage Alzheimer's patients, Leqembi is distributed through various channels and utilized by hospitals, clinics, and home health providers.
The market report provides comprehensive statistics, global size, regional shares, competitors' market share, detailed segments, and trends, offering a thorough perspective on current and future industry scenarios. The Leqembi market includes sales of oral tablets, injectable forms, and transdermal patches. Market value is derived from goods sold by manufacturers or creators, including related services, with revenues generated in specific geographies, excluding resales along the supply chain.
Key Topics Covered:
1. Executive Summary
2. Leqembi Market Characteristics
3. Leqembi Market Biologic Drug Characteristics
- 3.1. Molecule Type
- 3.2. Route of Administration (ROA)
- 3.3. Mechanism of Action (MOA)
- 3.4. Safety and Efficacy
4. Leqembi Market Trends and Strategies
5. Leqembi Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market
6. Global Leqembi Growth Analysis and Strategic Analysis Framework
- 6.1. Global Leqembi PESTEL Analysis
- 6.2. Analysis of End Use Industries
- 6.3. Global Leqembi Market Growth Rate Analysis
- 6.4. Global Leqembi Historic Market Size and Growth, 2019-2024, Value ($ Million)
- 6.5. Global Leqembi Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Million)
- 6.6. Global Leqembi Total Addressable Market (TAM)
7. Global Leqembi Pricing Analysis & Forecasts
8. Leqembi Market Segmentation
- 8.1. Global Leqembi Market, Segmentation by Formulation
- 8.2. Global Leqembi Market, Segmentation by Indication
- 8.3. Global Leqembi Market, Segmentation by Patient Demographics
- 8.4. Global Leqembi Market, Segmentation by Distribution Channel
- 8.5. Global Leqembi Market, Segmentation by End-User
9. Global Leqembi Epidemiology of Clinical Indications
- 9.1. Drug Side Effects
- 9.2. Incidence and Prevalence of Clinical Indications
10. Leqembi Market Regional and Country Analysis
- 10.1. Global Leqembi Market, Split by Region
- 10.2. Global Leqembi Market, Split by Country
For more information about this report visit https://www.researchandmarkets.com/r/iqrwwo
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
